Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

SUMMARY: BACKGROUND: Gout flares are driven by interleukin (IL)-1β. Dapansutrile inhibits the NLRP3 inflammasome and subsequent activation of IL-1β. In this study we aimed to investigate the safety and efficacy of orally administered dapansutrile in patients with a gout flare. METHODS: In this open-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Rheumatol
Main Authors: Klück, Viola, Jansen, Tim L Th A, Janssen, Matthijs, Comarniceanu, Antoaneta, Efdé, Monique, Tengesdal, Isak W, Schraa, Kiki, Cleophas, Maartje C P, Scribner, Curtis L, Skouras, Damaris B, Marchetti, Carlo, Dinarello, Charles A, Joosten, Leo A B
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523621/
https://ncbi.nlm.nih.gov/pubmed/33005902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/s2665-9913(20)30065-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados